Wize Pharma Inc. (OTCQB: WIZP), following the successful acquisition of Cosmos Capital Limited, a global Digital Infrastructure provider, with diversified operations across Cryptocurrency Mining and Digital Asset Management, has changed its name to Mawson Infrastructure Group Inc.,
| SYDNEY, March 24, 2021 /PRNewswire/ --Wize Pharma Inc. (OTCQB: WIZP), following the successful acquisition of Cosmos Capital Limited, a global Digital Infrastructure provider, with diversified operations across Cryptocurrency Mining and Digital Asset Management, has changed its name to Mawson Infrastructure Group Inc., to better reflect the company’s existing and future operations.
James Manning, CEO of Mawson Infrastructure, said: “Sir Douglas Mawson was an Australian hero – an explorer, geologist and academic, as well as a key expedition leader in the heroic age of Antarctic exploration. We aim to embody his grit, speed and determination in everything we do. Mawson operates physical infrastructure assets across the USA and Australia, as well as digital asset infrastructure globally. This name change better reflects our go forward philosophy and more accurately describes our activities moving forward.” About Mawson Infrastructure Mawson Infrastructure is a digital infrastructure provider, with diversified operations across Cryptocurrency Mining and Digital Asset Management. Headquartered in Sydney, Australia and operating across the USA and Australia, Mawson Infrastructure’s mission is to build a bridge between the rapidly emerging digital asset industry and traditional capital markets, with a strong focus on shareholder returns. Mawson matches energy infrastructure with next-generation mobile data centre solutions, enabling the proliferation of blockchain technology. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Mawson Infrastructure (the “Company”) cautions that statements in this report that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021, and in other filings that the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release. For all investor enquiries, please contact:
SOURCE Wize Pharma, Inc. | ||
Company Codes: OTC-PINK:WIZP, OTC-QB:WIZP, OtherOTC:WIZP |
View original content to download multimedia:
